SGMO Quote, Financials, Valuation and Earnings

Bionano Genomics has a net margin of -475.33% compared to Sangamo Therapeutics's net margin of -48.04%. Sangamo Therapeutics's return on equity of -269.87% beat Bionano Genomics's return on equity of -141.6%.

Sangamo Therapeutics has a consensus price target of $4.10, signalling upside risk potential of 751.86%. On the other hand Bionano Genomics has an analysts' consensus of $7.33 which suggests that it could grow by 115.69%. Given that Sangamo Therapeutics has higher upside potential than Bionano Genomics, analysts believe Sangamo Therapeutics is more attractive than Bionano Genomics.

Sangamo Therapeutics has a beta of 1.234, which suggesting that the stock is 23.402% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.207, suggesting its more volatile than the S&P 500 by 120.694%.

Sangamo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

Sangamo Therapeutics quarterly revenues are $6.4M, which are smaller than Bionano Genomics quarterly revenues of $6.5M. Sangamo Therapeutics's net income of -$30.6M is lower than Bionano Genomics's net income of -$3.1M. Notably, Sangamo Therapeutics's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics is 1.60x versus 0.17x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -475.33% compared to Sangamo Therapeutics's net margin of -30140.49%. Sangamo Therapeutics's return on equity of -269.87% beat Inovio Pharmaceuticals's return on equity of -125.47%.

Sangamo Therapeutics has a consensus price target of $4.10, signalling upside risk potential of 751.86%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.50 which suggests that it could grow by 459.7%. Given that Sangamo Therapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Sangamo Therapeutics is more attractive than Inovio Pharmaceuticals.

Sangamo Therapeutics has a beta of 1.234, which suggesting that the stock is 23.402% more volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.307, suggesting its more volatile than the S&P 500 by 30.734%.

Sangamo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Sangamo Therapeutics quarterly revenues are $6.4M, which are larger than Inovio Pharmaceuticals quarterly revenues of $65.3K. Sangamo Therapeutics's net income of -$30.6M is lower than Inovio Pharmaceuticals's net income of -$19.7M. Notably, Sangamo Therapeutics's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics is 1.60x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -475.33% compared to Sangamo Therapeutics's net margin of -35.79%. Sangamo Therapeutics's return on equity of -269.87% beat Protalix BioTherapeutics's return on equity of 10.9%.

Sangamo Therapeutics has a consensus price target of $4.10, signalling upside risk potential of 751.86%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 879.02%. Given that Protalix BioTherapeutics has higher upside potential than Sangamo Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Sangamo Therapeutics.

Sangamo Therapeutics has a beta of 1.234, which suggesting that the stock is 23.402% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

Sangamo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Sangamo Therapeutics quarterly revenues are $6.4M, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Sangamo Therapeutics's net income of -$30.6M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Sangamo Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 35.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics is 1.60x versus 2.01x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vaxart has a net margin of -475.33% compared to Sangamo Therapeutics's net margin of -74.68%. Sangamo Therapeutics's return on equity of -269.87% beat Vaxart's return on equity of -94.14%.

Sangamo Therapeutics has a consensus price target of $4.10, signalling upside risk potential of 751.86%. On the other hand Vaxart has an analysts' consensus of $4.67 which suggests that it could grow by 1074.6%. Given that Vaxart has higher upside potential than Sangamo Therapeutics, analysts believe Vaxart is more attractive than Sangamo Therapeutics.

Sangamo Therapeutics has a beta of 1.234, which suggesting that the stock is 23.402% more volatile than S&P 500. In comparison Vaxart has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.422%.

Sangamo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vaxart offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics pays -- of its earnings as a dividend. Vaxart pays out -- of its earnings as a dividend.

Sangamo Therapeutics quarterly revenues are $6.4M, which are smaller than Vaxart quarterly revenues of $20.9M. Sangamo Therapeutics's net income of -$30.6M is lower than Vaxart's net income of -$15.6M. Notably, Sangamo Therapeutics's price-to-earnings ratio is -- while Vaxart's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics is 1.60x versus 1.82x for Vaxart. Usually stocks with elevated PS ratios are considered overvalued.